SUPPLEMENTARY MATERIAL

Fig. S1. Absence of association of plasma oxysterols with plasma cholesterol or anti-oxidant capacity.

Fig. S2. Free cholesterol levels and LDL-stimulated cholesterol esterification in skin fibroblasts from NPC1 subjects.

Table S1. Plasma oxysterols in NPC1 subjects.

Type of file: figure
Label: S1, F1, F2
Filename: Ory_Supplemental figures 10.25.10.pdf

Table S1

Plasma oxysterols in NPC1 subjects

Oxysterol	ng/ml ± SEM
7α-HC	63.4 ± 11.5
7β-HC	214.6 ± 31.8
4β-HC	125.5 ± 46.2
3β,5α,6β-triol	358.0 ± 164.0
27-HC	77.7 ± 34.2
24(S)-HC	63.1 ± 23.0
20-S	31.4 ± 7.4
25-HC	7.3 ± 2.0
7α,27-HC	6.8 ± 1.3
7β,27-HC	3.9 ± 0.9
6-KC	22.2 ± 7.3
7-KC	804.1 ± 148.5



Fig. S1. Absence of association of plasma oxysterols with plasma cholesterol or anti-oxidant capacity.
(A) Plasma 3β,5α,6β-triol and (B) 7-KC levels in control and NPC1 subjects correlated with plasma total cholesterol levels. (C) Plasma 3β,5α,6β-triol and (D) 7-KC levels in control and NPC1 subjects normalized to plasma total cholesterol levels. (E) Comparison of plasma 3β,5α,6β-triol and 7-KC levels in control, NPC1 and Familial Hypercholesterolemia subjects. (F) Correlation of plasma 3β,5α,6β-triol, 7-KC and 24(S)-HC levels with Trolox equivalent antioxidant capacity (TEAC) of plasma in NPC1 subjects.



Fig. S2. Free cholesterol levels and LDL-stimulated cholesterol esterification in skin fibroblasts from NPC1 subjects. (A) Free cholesterol levels in skin fibroblasts cultured for 48h under lipoprotein-deficient conditions. (B) Rates of LDL-stimulated cholesterol esterification in skin fibroblasts from NPC1 subjects. (C) Correlation of rates of LDL-stimulated cholesterol esterification with free cholesterol accumulation in fibroblasts obtained from NPC1 subjects. Red symbol indicates WT fibroblasts. $p<0.01$.